Zalgen Labs, LLC
Germantown Innovation Center
20271 Goldenrod Lane, Suite 2083
Germantown
Maryland
20876
United States
Tel: 301-515-5554
Website: http://www.zalgenlabs.com/
Email: admin@zalgenlabs.com
About Zalgen Labs, LLC
Zalgen has core competency in the development of multiple platforms for generation of high quality recombinant proteins from difficult-to-express genes. Our proven approaches are supported by the successful development of first-to-field-use rapid diagnostic tests for Lassa hemorrhagic fever (LHF) by a consortium of academic, institutional, and biotechnology entities, led by one of our founders, Dr. Robert F. Garry (http://tulane.edu/som/cancer/robert-garry.cfm). These diagnostics are revolutionizing the understanding of epidemiological, immunological, and basic research notions in LHF, thus contributing to dramatic improvements in the management and successful outcome of this viral disease.YEAR FOUNDED:
2011
LEADERSHIP:
Founders: Robert F. Garry and Luis M. Branco
JOBS:
Please click here for Zalgen Labs job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW ZALGEN LABS:
Tweets by Zalgen Labs
7 articles about Zalgen Labs, LLC
-
Zalgen Immunotherapeutic Confers Complete Protection Against Advanced Multilineage Lassa Infections in Nonhuman Primates
8/18/2023
Zalgen Labs LLC today announced publication of data demonstrating that Arevirumab-3®, its lead immunotherapeutic candidate, is an effective therapeutic for the treatment of Lassa virus infections, with activity against all major viral lineages that cause severe disease in humans, and at very low dosages.
-
The CDC is taking a proactive stance and establishing a center that will use forecasting and outbreak analytics to guide public health decision-making.
-
Zalgen Awarded CEPI Contract to Provide Test Kits for Largest Ever Lassa Fever Study in West Africa
8/25/2021
Zalgen Labs LLC, a biotechnology and diagnostics company focused on preparedness for high impact, neglected infectious diseases including Lassa Fever, announced its contract with the Coalition for Epidemic Preparedness Innovations to further advance the development of vaccines against Lassa Fever in West Africa, a region where the disease is endemic.
-
Zalgen Labs Launches E-Commerce Platform For Hemorrhagic Fever Products
12/12/2016
-
FDA Completes Transfer Of Emergency Use Authorization For Reebov Ebola Antigen Rapid Test To Zalgen Labs
11/14/2016
-
Zalgen Labs And NOWDiagnostics Announce Strategic Collaboration To Advance Novel Rapid Diagnostic Tests For Tropical Diseases
10/27/2016
-
Zalgen Labs Introduces Viral Diagnostics Business, Opens Advanced Product Development Center In Colorado
8/22/2016